JNJ · News · 20260914N

Rybrevant Competitive Pressure

JOHNSON & JOHNSON · 2026-09-14 · Importance 17 · Surprise 24

Third-party reporting indicated that Johnson & Johnson expects its portfolio and pipeline to support growth despite biosimilar competition for STELARA. The reported competitive pressure is concentrated on STELARA, while management is positioning newer medicines, medical devices, and development programs as offsets. The item did not identify a specific biosimilar entrant, pricing change, or market-share impact.